Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically...

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Solid tumors exhibit significant heterogeneity, expressing diverse antigens.
• This heterogeneity poses a challenge for current chimeric antigen receptor (CAR) T-cell therapies, often leading to antigen escape and disease recurrence.
• Existing CAR T-cell strategies struggle to effectively target the multiple clones within heterogeneous solid tumors.

Purpose of the Study:

• To develop a novel strategy to enhance CAR T-cell therapy efficacy against heterogeneous solid tumors.
• To investigate the potential of bispecific adapters to bridge engineered T-cells to diverse tumor antigens.
• To overcome tumor antigen escape mechanisms that limit the success of current CAR T-cell treatments.

Main Methods:

• Utilized a cocktail of low-molecular-weight bispecific adapters, each linking fluorescein to a unique tumor-specific ligand.
• Engineered T-cells expressed an antifluorescein CAR to bind these adapters.
• Tested the efficacy of this system in NSG mice bearing concurrently implanted, antigenically diverse solid tumors.

Main Results:

• The bispecific adapter cocktail successfully bridged antifluorescein CAR T-cells to cancer cells expressing unique antigens.
• A single type of antifluorescein CAR T-cell eradicated diverse, antigenically distinct solid tumors.
• Demonstrated the formation of an immunologic synapse between CAR T-cells and cancer cells via the adapters.

Conclusions:

• A carefully designed cocktail of bispecific adapters combined with antifluorescein CAR T-cells can overcome tumor antigen escape.
• This strategy shows potential for broader applicability in treating cancers where standard CAR T-cell therapy has previously failed.
• Highlights the potential of bispecific adapters to augment CAR T-cell therapies against heterogeneous tumors, improving treatment outcomes.